347 related articles for article (PubMed ID: 21910797)
1. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.
McLellan B; Kerr H
Dermatol Ther; 2011; 24(4):396-400. PubMed ID: 21910797
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
3. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Lipworth AD; Robert C; Zhu AX
Oncology; 2009; 77(5):257-71. PubMed ID: 19923864
[TBL] [Abstract][Full Text] [Related]
4. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
Lacouture ME; Reilly LM; Gerami P; Guitart J
Ann Oncol; 2008 Nov; 19(11):1955-61. PubMed ID: 18550575
[TBL] [Abstract][Full Text] [Related]
5. [Hand-foot syndrome after administration of tyrosinkinase inhibitors].
Bednaríková D; Kocák I
Klin Onkol; 2010; 23(5):300-5. PubMed ID: 21061680
[TBL] [Abstract][Full Text] [Related]
6. [Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib].
Wollenberg A; Staehler M; Eames T
Hautarzt; 2010 Aug; 61(8):662-7. PubMed ID: 20631979
[TBL] [Abstract][Full Text] [Related]
7. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lacouture ME; Wu S; Robert C; Atkins MB; Kong HH; Guitart J; Garbe C; Hauschild A; Puzanov I; Alexandrescu DT; Anderson RT; Wood L; Dutcher JP
Oncologist; 2008 Sep; 13(9):1001-11. PubMed ID: 18779536
[TBL] [Abstract][Full Text] [Related]
8. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
9. Interstitial granulomatous drug reaction to sorafenib.
Martínez-Morán C; Nájera L; Ruiz-Casado AI; Romero-Maté A; Espinosa P; Meseguer-Yebra C; Córdoba S; Borbujo JM
Arch Dermatol; 2011 Sep; 147(9):1118-9. PubMed ID: 21931061
[No Abstract] [Full Text] [Related]
10. Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
Bukowski RM
Clin Genitourin Cancer; 2009 Jan; 7(1):9-10. PubMed ID: 19213661
[No Abstract] [Full Text] [Related]
11. [Cutaneous side effects of sorafenib and sunitinib].
Autier J; Mateus C; Wechsler J; Spatz A; Robert C
Ann Dermatol Venereol; 2008 Feb; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102
[No Abstract] [Full Text] [Related]
12. The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life.
Nardone B; Hensley JR; Kulik L; West DP; Mulcahy M; Rademaker A; Lacouture ME
J Drugs Dermatol; 2012 Nov; 11(11):e61-5. PubMed ID: 23135095
[TBL] [Abstract][Full Text] [Related]
13. Severe sorafenib-induced hand-foot skin reaction.
Cuesta L; Betlloch I; Toledo F; Latorre N; Monteagudo A
Dermatol Online J; 2011 May; 17(5):14. PubMed ID: 21635836
[TBL] [Abstract][Full Text] [Related]
14. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
Yang CH; Lin WC; Chuang CK; Chang YC; Pang ST; Lin YC; Kuo TT; Hsieh JJ; Chang JW
Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211
[TBL] [Abstract][Full Text] [Related]
15. Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
Ahn HK; Lee S; Sun JM; Lee J; Park SH; Park JO; Park YS; Kang WK; Lim HY
Invest New Drugs; 2012 Aug; 30(4):1768-72. PubMed ID: 21720741
[No Abstract] [Full Text] [Related]
16. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
Autier J; Escudier B; Wechsler J; Spatz A; Robert C
Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
[TBL] [Abstract][Full Text] [Related]
17. Erythema multiforme-like drug reaction to sorafenib.
Lewin J; Farley-Loftus R; Pomeranz MK
J Drugs Dermatol; 2011 Dec; 10(12):1462-3. PubMed ID: 22134572
[TBL] [Abstract][Full Text] [Related]
18. [Hand-foot syndrome and sorafenib].
Milano G; Mortier L; Digue L; Desmedt E; Ravaud A
Bull Cancer; 2009 Feb; 96(2):191-7. PubMed ID: 19258226
[TBL] [Abstract][Full Text] [Related]
19. Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction.
Jain L; Gardner ER; Figg WD; Chernick MS; Kong HH
Pharmacotherapy; 2010 Jan; 30(1):52-6. PubMed ID: 20030473
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?
Sibaud V; Delord JP; Chevreau C
Target Oncol; 2009 Dec; 4(4):307-10. PubMed ID: 19894099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]